Lee Alex, Huang Paul, DeMatteo Ronald P, Pollack Seth M
From the Department of Medical Oncology, Royal Marsden Hospital London, United Kingdom; Institute of Cancer Research, London, United Kingdom; Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY; Fred Hutchinson Cancer Research Center, Division of Oncology, University of Washington, Seattle, WA.
Am Soc Clin Oncol Educ Book. 2016;35:281-90. doi: 10.1200/EDBK_157439.
Despite the advances taking place for patients with many types of cancer, to date there has been little success in meeting the great need for novel treatments of advanced soft tissue sarcoma with effective immunologic therapies. Here, we review recent clinical and preclinical data that indicate immune responses against sarcomas occur spontaneously and can also be successfully provoked. Efforts to manipulate the sarcoma immune microenvironment have the potential to eradicate disease and may also sensitize tumors to other tumor-targeted immunotherapeutic approaches. Other approaches, including vaccines and genetic engineering of T cells, offer a promising opportunity to actively direct cytotoxic lymphocytes toward antigen-bearing sarcomas. Drawing parallels with recent advances made in other cancer types, we identify ways in which sarcomas can be included in the ongoing immunotherapy revolution.
尽管针对多种癌症患者已取得了进展,但迄今为止,在满足晚期软组织肉瘤对新型有效免疫疗法的巨大需求方面几乎没有取得成功。在此,我们回顾了近期的临床和临床前数据,这些数据表明针对肉瘤的免疫反应会自发发生,也可以被成功激发。操纵肉瘤免疫微环境的努力有可能根除疾病,还可能使肿瘤对其他肿瘤靶向免疫治疗方法敏感。其他方法,包括疫苗和T细胞基因工程,为将细胞毒性淋巴细胞主动导向携带抗原的肉瘤提供了一个有前景的机会。与其他癌症类型的近期进展相比较,我们确定了将肉瘤纳入正在进行的免疫治疗革命的方法。